In our July issue of Pharmaceutical Executive FEATURES Cover Story Pharm Exec’s Emerging Pharma Leaders 2015 Pharm Exec Editors
This year’s group of Emerging Pharma Leaders, selected by our editorial staff, adds to a list of more than 200 alumni dating back to June 2008. We called that first cohort of leaders “the change generation” and that description remains apt today. What is different is a greater diversity in leader backgrounds and the skills required to advance to the “c-suite”.
Recruitment and Retention Building Tomorrow’s Biopharma Workforce William Looney
In a knowledge industry like biopharma, people are the intangible asset that marks the difference between a status quo or standout performance. Pharm Exec recently convened a panel of industry team leaders and HR specialists at St. Joseph’s University to parse out some useful best practices in three key areas: talent recruitment and retention; skills training; and workforce diversity.
Investment Confronting the Post-Grant Threat Brian W. Nolan Recent activities by investment firms have biopharmaceutical companies crying foul and seeking relief from Congress. The actions generating angst among industry insiders are investment firms filing inter partes review (IPR) petitions seeking to invalidate biopharma patents. Such challenges are spurring the industry into action to protect its drug franchises.
ALSO IN THIS ISSUE The Human Chain: 2015’s Emerging Pharma Leaders William Looney
Amid the release Pharm Exec’s Emerging Pharma Leaders 2015, William Looney considers what will determine true leadership in big Pharma in the years ahead.
Too Many Breakthroughs? Jill Wechsler
FDA wants pharma to be more selective in seeking special status for promising therapies.